GSK plc. and Alector, Inc. shared results from the INFRONT-3 trial for latozinemab in frontotemporal dementia caused by FTD-GRN. While the treatment improved plasma progranulin concentrations, it did not slow disease progression. No significant treatment-related effects were seen in secondary and exploratory endpoints. Safety data showed no major concerns, but further analysis is ongoing. Due to overall findings, the open-label extension and continuation study for latozinemab will be stopped. Stay updated on health news at rttnews.com. (Words: 84)

Read more at Nasdaq: GSK : Latozinemab Fails To Meet Clinical Endpoint In INFRONT-3 FTD-GRN Trial